Vontobel Holding Ltd. Acquires New Shares in Takeda Pharmaceutical Co. (NYSE:TAK)

Vontobel Holding Ltd. acquired a new stake in Takeda Pharmaceutical Co. (NYSE:TAK) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 17,619 shares of the company’s stock, valued at approximately $262,000.

A number of other large investors have also made changes to their positions in TAK. First Trust Advisors LP boosted its stake in Takeda Pharmaceutical by 2.0% in the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company’s stock worth $42,910,000 after purchasing an additional 62,718 shares during the period. Northern Trust Corp boosted its stake in Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company’s stock worth $24,806,000 after purchasing an additional 238,161 shares during the period. Soleus Capital Management L.P. boosted its stake in Takeda Pharmaceutical by 136.0% in the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company’s stock worth $15,623,000 after purchasing an additional 680,000 shares during the period. Summit Global Investments boosted its stake in Takeda Pharmaceutical by 75.5% in the 4th quarter. Summit Global Investments now owns 729,200 shares of the company’s stock worth $9,655,000 after purchasing an additional 313,642 shares during the period. Finally, Toronto Dominion Bank acquired a new position in Takeda Pharmaceutical in the 4th quarter worth $6,760,000. Institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $15.02 on Wednesday. The firm has a market cap of $47.79 billion, a PE ratio of 68.28 and a beta of 0.23. The company has a current ratio of 1.01, a quick ratio of 0.52 and a debt-to-equity ratio of 0.57. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.53. The company has a fifty day moving average price of $14.86 and a 200 day moving average price of $14.35.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Research analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.